Proactive - Interviews for investors

Elixir Energy Ltd (ASX:EXR, OTC:ELXPF) managing director Neil Young joins Proactive’s Tylah Tully to discuss the non-binding Memorandum of Understanding (MoU) the company has entered with the Australian Gas Infrastructure Group (AGIG) to explore the development of gas infrastructure in Queensland’s Taroom Trough.

This infrastructure would support future gas production from Elixir’s Grandis Gas Project in the emerging region.

The MoU was signed with AGI Development Group Pty Ltd, a subsidiary of AGIG, which is among Australia’s largest gas infrastructure businesses.

The key areas under consideration include a new gas transmission pipeline connecting to the Wallumbilla Hub, along with processing, compression and gas storage facilities.

Young expressed satisfaction with the MoU, emphasising its significance in boosting confidence about the potential of Project Grandis and the wider Taroom Trough region.

He also mentioned the possibility of involving other asset owners and government entities in the process.

AGIG is a major infrastructure provider in Australia, servicing more than two million customers through various assets, including the Dampier to Bunbury Natural Gas Pipeline and the Tubridgi Gas Storage Facility in Western Australia, as well as the Wide Bay Gas Pipeline in Queensland.

#ProactiveInvestors #ElixirEnergy #ASX #AGIG #GasInfrastructure, #TaroomTrough, #GrandisGasProject, #GasTransmission, #QueenslandGas, #EnergySector, #NaturalGas, #MoU, #WallumbillaHub, #EnergyDevelopment, #GasProcessing, #GasCompression, #GasStorage, #AustralianEnergy, #EnergyPartnership, #PipelineDevelopment, #RenewableEnergy, #CleanEnergy

Comet Ridge Ltd (ASX:COI) managing director Tor McCaul sits down with Proactive’s Tylah Tully to give an overview of the company, its projects and investor case.

McCaul also provided an update on drilling operations at Mahalo East where Mahalo East 1 vertical well spudding has started.

This is part of the company's broader exploration efforts in the northern Mahalo Hub, where Comet Ridge holds 100% equity in four ATP areas.

The Mahalo East 1 well is about 25 kilometres east of the Mahalo North Pilot Scheme, where 2P and 3P Reserves have already been certified.

The well has two key objectives: to gather core and log data across the coal reservoirs and to serve as a production well for the upcoming Mahalo East 2 lateral well. The well will be drilled to a total depth of 400 metres, intersecting four coal reservoirs.

McCaul highlighted the importance of this work, noting that the project received a $5 million grant from Queensland’s Frontier Gas Exploration Grants Program.

The aim is to gather technical data to integrate Mahalo East into the company's future development plans. Updates will be provided as drilling progresses.

#ProactiveInvestors #CometRidge #ASX #MahaloEast #GasExploration #QueenslandEnergy #MahaloHub #ATP2061 #GasReserves #FrontierGasGrants #EnergyExploration #CoalReservoirs #CondorEnergy #DrillingOperations #NaturalGas #EnergyDevelopment #GasExplorationUpdates #QueenslandGas #CometRidgeLimited #EnergySector #AustralianGasExploration #GasFairway

Ocean Power Technologies CEO Philipp Stratmann joined Steve Darling from Proactive shared exciting developments announcing the shipment of a WAM-V Unmanned Surface Vehicle to the UAE. This follows the company's June 2024 partnership with Unique Group, a UAE-based offshore services provider. OPT and Unique Group will exhibit the 22ft WAM-V at the upcoming ADIPEC event in Abu Dhabi from November 4-7, 2024, showcasing cutting-edge energy innovations alongside over 2,200 global organizations.

Stratmann also revealed that OPT has signed an agreement with 3B General Trading & Contracting to explore offshore energy and maritime projects in Kuwait. The partnership aims to deploy OPT’s autonomous WAM-V vehicles and Next Generation PowerBuoys equipped with AI-powered Merrows, enhancing offshore energy generation and ocean intelligence capabilities in the growing Kuwaiti market.

#proactiveinvestors #oceanpowertechnologiesinc #nyseamerican #optt #PhillipStratmann, #USGovernmentContract, #OffshoreAutonomy, #MaritimeSecurity, #CommercialPlatforms, #GrowthStrategy, #BuoyBusiness, #VehicleBusiness, #InternationalExpansion, #ReadyToDeploy, #AutonomousSystems, #EconomicImpact, #ShippingLanes, #FreedomOfNavigation, #CostEffectiveSolutions, #LowEmissionTech, #SecurityInnovation, #GlobalShipping, #ProactiveNewsroom#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

OmniQ CEO Shai Lustgarten joined Steve Darling from Proactive to outline the company's innovative approach to automation through its proprietary machine vision system, which utilizes AI to detect and identify objects without human intervention. Lustgarten emphasized OmniQ’s nine patented technologies, designed to improve efficiency across various sectors.

One key application, Q Shield, is making a notable impact in public safety, aiding municipalities in identifying stolen vehicles and solving missing person cases. He also highlighted OmniQ's collaboration with NEC, leveraging OmniQ's sensor technology to enhance facial recognition systems.

Looking ahead, Lustgarten revealed OmniQ’s strategic shift from one-time sales to recurring revenue streams, positioning the company for scalability and profitability, particularly in public safety and traffic management sectors.

#proactiveinvestors #omniqcorp #otcqb #omqs

#AItechnology #Automation #PublicSafety #MachineVision #AI #TechInnovation #FacialRecognition #QShield #RecurringRevenue #SmartCities #ProactiveInvestors

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Adriatic Metals PLC (LSE:ADT1, ASX:ADT, OTCQX:ADMLF) CEO Laura Tyler talked with Proactive's Stephen Gunnion about the company's recent developments, particularly the ramp-up towards commercial production at the Vares Silver Project.

Tyler, who recently took over the leadership role, shared insights on her extensive experience in polymetallic mining, including roles at BHP, and how it is shaping her vision for Adriatic Metals.

She discussed the key milestones at Vares, noting the company's successful stope blasts in August and September, and its preparations to reach full production by December. She emphasised how despite some weather-related challenges, Adriatic Metals remains on track to achieve its goals with a motivated workforce and well-established infrastructure.

Looking ahead, Tyler highlighted the company's focus on safely ramping up production, reducing debt, and exploring incremental growth opportunities, including exploration projects and potential regional mergers and acquisitions.

"We've got all the key infrastructure in place to make this a success," Tyler noted. She also spoke on the strong governmental support for European mining, positioning Adriatic Metals well for future growth.

For more updates, don't forget to visit Proactive’s YouTube channel for more videos, give the video a like, subscribe to the channel, and enable notifications for future content.

#AdriaticMetals #LauraTyler #VaresProject #SilverMining #MiningUpdates #CommercialProduction #PolymetallicMining #EuropeanMining #MiningIndustry #CriticalMinerals#ProactiveInvestors #stockmarketnews

Proactive’s Billy Farrington takes Stephen Gunnion through Bitcoin's performance over the past week. Farrington shared that Bitcoin has seen one of its strongest weeks in recent months, rising by 12.5% since last Friday.

Despite initial expectations of stability until the US elections, the surge in Bitcoin appears to be influenced by the rising odds of a Donald Trump victory in the upcoming elections. Farrington explained, “Trump has positioned himself as the pro-crypto candidate, which has likely galvanised the Bitcoin price.”

Additionally, there has been a revitalization of inflows into Bitcoin ETFs, with approximately $1 billion flowing in this week alone. This resurgence in ETF demand has been a significant tailwind for Bitcoin, according to Farrington, who believes that momentum may continue.

Be sure to watch the full video for deeper insights into Bitcoin's market movements, and the potential implications of US political developments.

Don’t forget to like this video, subscribe to Proactive's YouTube channel, and enable notifications to stay updated on all future content.

#Bitcoin #CryptoNews #BitcoinETF #ProCrypto #USPolitics #CryptoMarket #BitcoinSurge #Cryptocurrency #BTC #ETFinflows #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Frontier IP Group PLC (AIM:FIPP) portfolio company The Vaccine Group (TVG) has secured over £400,000 in funding through an Innovate UK Smart Grant. CEO Jeremy Salt told Proactive's Stephen Gunnion the funding will support the development of novel herpesvirus vaccine technology aimed at combating two critical cattle diseases: bovine respiratory syncytial virus (BRSV) and lumpy skin disease.

Salt highlighted the commercial importance of these diseases, particularly noting that BRSV impacts nearly 2 million calves annually in the UK alone, costing the industry £54 million per year. This grant will allow The Vaccine Group to move from laboratory testing to real-world animal trials in collaboration with the Animal and Plant Health Agency (APHA) and The Pirbright Institute.

Salt also shared updates on other key projects, including the company's efforts in developing vaccines for companion animals such as cats, dogs, and horses, as well as an ongoing Innovate UK grant to target Streptococcus suis in pigs.

Don't forget to give this video a like, subscribe to the Proactive channel, and enable notifications to stay updated on more interviews like this one!"

#VaccineDevelopment #AnimalHealth #BovineDiseases #InnovateUK #LumpySkinDisease #BRSV #CompanionAnimalVaccines #JeremySalt #TheVaccineGroup #FrontierIP #AnimalVaccines

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Candel Therapeuitcs CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to share the company's cutting-edge advancements in viral therapies targeting difficult-to-treat cancers such as prostate, pancreatic, and brain cancers. Candel’s lead compound leverages an innovative in situ vaccination approach, enabling the patient’s immune system to combat both local tumors and distant metastases. With two large randomized prostate cancer trials set to deliver results by year-end, this represents a significant opportunity to address unmet medical needs.

Dr. Tak also highlighted the potential of CAN-3110, an engineered herpes simplex virus aimed at treating glioblastoma, with new data on serial injections to be unveiled at an upcoming international conference. The therapy shows promise for expansion into melanoma and other cancers. He noted that positive trial outcomes could lead to regional partnerships to accelerate global patient access.

Looking ahead, Candel anticipates further data from its pipeline, particularly in pancreatic and lung cancers, by early 2024. Dr. Tak emphasized the company’s strategic focus on partnerships to scale its operations, positioning Candel Therapeutics for significant growth and a potential transformation into a broader pharmaceutical player over the next six months.

#proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Alvopetro Energy CEO Corey Ruttan joined Steve Darling from Proactive to share details on the company’s operational performance in September 2024 and provide an update on its ongoing drilling activities. The company reported a notable increase in production, with Q3 sales volumes averaging 2,106 boepd, marking a 29% jump from 1,629 boepd in Q2. In September, sales volumes reached an average of 1,963 boepd, which included 11.2 MMcfpd of natural gas, 87 bopd of condensate, and 9 bopd of oil.

Ruttan also provided insight into the initial completion of the 183-A3 well. The well began production in September and is currently cleaning up as it produces both natural gas and completion fluids. Over the last 72 hours of continuous operation, the well has averaged 2.1 MMcfpd of gas, along with 175 barrels of completion fluid and 50 barrels of condensate per day. The flowing wellhead pressure during this period has averaged 1,195 psi, with a final value of 1,150 psi, and production has been controlled with an 18/64" choke.

The company also completed a recompletion of the 183-1 well, but the zone encountered is currently producing only water. Moving forward, Alvopetro plans to monitor the 183-A3 well’s performance before designing an intervention for the 183-1 well. Additionally, they aim to begin a new drilling project up-dip of the 183-A3 well from the prebuilt 183-D pad location.

#proactiveinvestors #alvopetroenergyltd #tsxv #alv #otcqx #alvof #OilAndGas #BrazilNaturalGas #EnergyProduction #CEOInterview #Q32024 #ProactiveInvestors #GasPlantCapacity #OrganicGrowth #EnergyStocks

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Proactive’s Tylah Tully breaks down Just the Facts of the latest news from Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF).

The company has successfully completed the safety evaluation for its intravenous psilocin formulation, TRP-8803, following a Phase 1b clinical trial.

This milestone demonstrates that the treatment was generally safe and well-tolerated, paving the way for further clinical studies.

The trial began in June 2024 at CMAX Clinical Research in Adelaide and involved eleven healthy participants who received varying doses of the IV-infused psilocin over a period of up to 150 minutes.

The result marks a significant step in Tryptamine's clinical program and will guide the design of upcoming Phase 2 trials.

The company plans to build on its earlier success with the oral formulation, TRP-8802, which has shown potential in treating Binge Eating Disorder and Fibromyalgia.

The intravenous version, TRP-8803, is expected to provide several advantages over oral psilocybin, such as a faster onset, shorter duration and better control over the therapeutic experience.

The next phase will involve additional trials and ongoing regulatory engagement.

#ProactiveInvestprs #TryptamineTherapeutics #ASX #JusttheFacts #PsilocybinTherapy #Phase1Trial #TRP8803 #PsilocinFormulation #SafetyEvaluation #BingeEatingDisorder #FibromyalgiaTreatment #PsychedelicTherapy #ClinicalTrials #Pharmacokinetics #PsilocybinResearch #HealthcareInnovation #CMAXResearch #MentalHealth #PsilocybinInfusion #SRCApproval #PsilocybinTherapeutics #TRP8802 #ClinicalDevelopment